Tags

Type your tag names separated by a space and hit enter

Oxidative stress markers are increased in patients with mastocytosis.
Allergy 2015; 70(4):436-42A

Abstract

BACKGROUND

Mastocytosis is characterized by clonal proliferation of mast cells limited to the skin (cutaneous mastocytosis: CM and mastocytosis in the skin: MIS) and/or involving internal organs (systemic mastocytosis: SM). Oxidative stress occurring in various inflammatory and neoplastic disorders causes molecular damage with the production of advanced oxidation protein products (AOPPs) and advanced glycation end products (AGEs). We evaluated these markers of oxidative stress in patients with CM/MIS and SM and correlated their levels with the presence of symptoms related to mast cell activation.

METHODS

Serum levels of AOPPs and AGEs in 34 patients with mastocytosis (23 CM/MIS and 11 SM) and 27 healthy controls were measured by spectrofluorimetric and spectrophotometric methods. Serum tryptase levels were measured by immunofluorescence.

RESULTS

Serum AOPPs, but not AGEs, were significantly higher in patients with mastocytosis as compared to healthy controls. While serum tryptase levels were higher in patients with SM as compared to those with CM/MIS, there was no difference in AOPP and AGE concentrations between these two groups of patients. Patients with recurrent mediator-related symptoms had lower AOPPs and AGEs as compared to patients without symptoms. AOPPs and AGEs were inversely correlated with the severity of symptoms, and in patients with symptoms, AOPPs correlated with tryptase levels.

DISCUSSION

Our data show that mastocytosis is associated with a state of increased oxidative stress that, in patients with mediator-related symptoms, correlates with mast cell burden as assessed by tryptase. Patients with symptoms presumably have an adaptive response resulting in lower blood levels of AOPPs and AGEs.

Authors+Show Affiliations

Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; Institute of Clinical Physiology, IFC CNR, Messina Unit, Messina, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25630934

Citation

Gangemi, S, et al. "Oxidative Stress Markers Are Increased in Patients With Mastocytosis." Allergy, vol. 70, no. 4, 2015, pp. 436-42.
Gangemi S, Minciullo PL, Magliacane D, et al. Oxidative stress markers are increased in patients with mastocytosis. Allergy. 2015;70(4):436-42.
Gangemi, S., Minciullo, P. L., Magliacane, D., Saitta, S., Loffredo, S., Saija, A., ... Triggiani, M. (2015). Oxidative stress markers are increased in patients with mastocytosis. Allergy, 70(4), pp. 436-42. doi:10.1111/all.12571.
Gangemi S, et al. Oxidative Stress Markers Are Increased in Patients With Mastocytosis. Allergy. 2015;70(4):436-42. PubMed PMID: 25630934.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oxidative stress markers are increased in patients with mastocytosis. AU - Gangemi,S, AU - Minciullo,P L, AU - Magliacane,D, AU - Saitta,S, AU - Loffredo,S, AU - Saija,A, AU - Cristani,M, AU - Marone,G, AU - Triggiani,M, Y1 - 2015/01/29/ PY - 2014/12/30/accepted PY - 2015/1/30/entrez PY - 2015/1/30/pubmed PY - 2015/12/19/medline KW - advanced glycation end product KW - advanced oxidation protein product KW - mast cell KW - mastocytosis KW - oxidative stress SP - 436 EP - 42 JF - Allergy JO - Allergy VL - 70 IS - 4 N2 - BACKGROUND: Mastocytosis is characterized by clonal proliferation of mast cells limited to the skin (cutaneous mastocytosis: CM and mastocytosis in the skin: MIS) and/or involving internal organs (systemic mastocytosis: SM). Oxidative stress occurring in various inflammatory and neoplastic disorders causes molecular damage with the production of advanced oxidation protein products (AOPPs) and advanced glycation end products (AGEs). We evaluated these markers of oxidative stress in patients with CM/MIS and SM and correlated their levels with the presence of symptoms related to mast cell activation. METHODS: Serum levels of AOPPs and AGEs in 34 patients with mastocytosis (23 CM/MIS and 11 SM) and 27 healthy controls were measured by spectrofluorimetric and spectrophotometric methods. Serum tryptase levels were measured by immunofluorescence. RESULTS: Serum AOPPs, but not AGEs, were significantly higher in patients with mastocytosis as compared to healthy controls. While serum tryptase levels were higher in patients with SM as compared to those with CM/MIS, there was no difference in AOPP and AGE concentrations between these two groups of patients. Patients with recurrent mediator-related symptoms had lower AOPPs and AGEs as compared to patients without symptoms. AOPPs and AGEs were inversely correlated with the severity of symptoms, and in patients with symptoms, AOPPs correlated with tryptase levels. DISCUSSION: Our data show that mastocytosis is associated with a state of increased oxidative stress that, in patients with mediator-related symptoms, correlates with mast cell burden as assessed by tryptase. Patients with symptoms presumably have an adaptive response resulting in lower blood levels of AOPPs and AGEs. SN - 1398-9995 UR - https://www.unboundmedicine.com/medline/citation/25630934/Oxidative_stress_markers_are_increased_in_patients_with_mastocytosis_ L2 - https://doi.org/10.1111/all.12571 DB - PRIME DP - Unbound Medicine ER -